Loading…
Don’t miss your opportunity to be a part of this event, now a highly anticipated Campbell tradition, a decade in the making!
More information at: library.campbell.edu/symposium2020
Back To Schedule
Friday, March 27 • 08:00 - 17:00
[VIRTUAL] Cost Analysis of Direct Oral Anticoagulants versus Enoxaparin for the Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Medically ill patients present a high risk for venous thromboembolism (VTE). Three medications (betrixaban, rivaroxaban, enoxaparin) are currently approved as prophylactic treatments against VTE. This study examined total care costs associated with each treatment. Analyses was performed by constructing decision-tree models incorporating clinical outcome probabilities and costs of healthcare resource consumption. Monte Carlo analyses using 10,000 subject simulations with sensitivity analyses was performed. The expected value (EV), or lowest cost strategy, per subject favored enoxaparin over betrixaban ($1,046 versus $1,209; 13.4% difference); and enoxaparin over rivaroxaban ($1,271 versus $1,650; 22.3% difference). These results are important in clinical and formulary decisions.

LINK TO VIDEO PRESENTATION


Friday March 27, 2020 08:00 - 17:00 EDT
Online